Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.

Innovation to commercialization

1,173 views

Published on

December 8th 2010: The 6th annual Dutch Life Sciences and Health conference was held in de Beurs van Berlage, Amsterdam. Willem de Laat, Managing Director at Life Sciences Health, talks about 'Innovation to commercialization'.

Published in: Health & Medicine
  • Be the first to comment

  • Be the first to like this

Innovation to commercialization

  1. 1. From innovation to commercialization Willem de Laat Managing Director Life Sciences & Health 8 December 2010
  2. 2. From innovation to commercialization
  3. 3. Global biomedical trends <ul><li>1 Trillion $ sales in 2014 </li></ul><ul><li>150 billion $ patent expirations </li></ul><ul><li>Ongoing consolidation </li></ul><ul><li>75% diseases without cure </li></ul><ul><li>Healthy ageing </li></ul><ul><li>Strong R&D investment </li></ul><ul><li>Ref.: Scrip News, April 2010 </li></ul>
  4. 4. Global R&D spending 1. Roche - $8.7B 2. Pfizer - $7.4B 3. Novartis  - $7.06B 4. Johnson & Johnson  - $6.66B 5. Sanofi-Aventis - $6.25B 6. GlaxoSmithKline -  $5.59B 7. Merck  - $5.58B 8. Takeda Pharmaceuticals - $4.64B 9. AstraZeneca - $4.23B 10. Eli Lilly - $4.13B 11. Bristol-Myers Squibb - $3.48B 12. Boehringer Ingelheim  - $3.03B 13. Abbott Laboratories - $2.61B 14. Daiichi Sankyo - $1.89B 15. Astellas Pharma - $1.63B
  5. 5. H ealth-related life sciences : an important sector in the Dutch economy Drugs Diagnostics Devices Companies Revenues FTE Other Total Source: EIM study for EZ [2006] , Voorstel LSG [2006] Preliminary data Biotech Outlook 2011 430 390 75 935 40 12.0 bn 2.7 bn 0.6 bn 15.7 bn 0.4 bn 37,000 12,000 54,600 3,400 ± 150 companies highly innovative Update 2010: >200 companies highly innovative 3% of GDP 2,200
  6. 6. The Dutch life sciences and health innovation cluster builds upon a strong knowledge base Excellent biobanks and ‘real life’ data infrastructure 120 mile radius Global players & very high concentration of SMEs Excellent universities
  7. 7. 5 of the top 10 European biotech deals are with Dutch companies, with a total value exceeding USD 2 billion
  8. 8. But....the consolidation changing environment has impact on the Netherlands Organon Solvay Crucell
  9. 9. Life Sciences & Health Innovation Program Improving the investment and innovation climate in the Dutch life sciences and health sector Hier komt een screenshot van de homepage 7 dec 5000+ unique visitors/month Database for subsidies and funding Benchmark study on clinical trial performance to map the competitive position of the Netherlands BIO - E UROPE S PRING MARCH 14-16, 2011, MILAN, ITALY Thomson Pharma Bio International Convention, Chicago, 2010
  10. 10. Biotech Outlook 2011 will be launched in Q1 next year <ul><li>Improved cluster assessment method </li></ul><ul><ul><li>Cluster size, output & investments </li></ul></ul><ul><ul><li>Context with major events </li></ul></ul><ul><ul><li>Comparison with international clusters </li></ul></ul><ul><li>Cooperation with international academic institutes </li></ul><ul><li>Cooperation on methodology with Council of European BioRegions </li></ul>Progress
  11. 11. Sector vision 300 downloads
  12. 12. “ TOPGEBIED LIFE SCIENCES” We have to Build, Nurture and Promote it together Health & Wealth
  13. 13. <ul><li>FEN-PHEN CASE (Wyeth) </li></ul><ul><li>Primary Pulmonary Hypertension on anti-obesity drug </li></ul><ul><li>62 deaths before label change (1994) </li></ul><ul><li>First court case (Billiton, Texas) $20 million </li></ul><ul><li>20,000 claims < 1 month </li></ul><ul><li>Discovery / browser /20,000 emails </li></ul><ul><li>Wyeths prior knowledge exposed </li></ul><ul><li>First settlement $1 billion </li></ul><ul><li>Reservations in Liability reserve fund total $21 billion </li></ul><ul><li>Stockprice decreased 50% </li></ul>
  14. 14. www.lifescienceshealth.com

×